The 6 Dimensions Capital-backed cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.

6 Dimensions Capital, the investment firm co-founded by pharmaceutical company WuXi AppTec, will have a chance to exit US-based immuno-oncology drug developer iTeos Therapeutics, which filed for a $100m initial public offering on Wednesday. Founded in 2011, iTeos is working on cancer immunotherapies and plans to channel the IPO proceeds into the clinical development of…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.